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ABSTRACT 
 
Natural killer (NK) cells are lymphocytes endowed with cytotoxicity against aberrant cells, 
including transformed and virus-infected cells. NK cell function is dictated by a fine-tuned 
interplay between activating and inhibitory receptors expressed on the NK cell surface. While the 
different activating receptors interact with unique ligands present on healthy or transformed cells, 
inhibitory NKG2A and killer immunoglobulin-like receptors (KIRs) invariably recognize HLA 
class I molecules. The purpose of this thesis was to elucidate how interactions between inhibitory 
NK cell receptors and HLA class I impact on anti-leukemic functions of NK cells and on NK 
cell-mediated termination of inflammation. In a phase IV trial, 81 AML patients received 
histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) for the prevention of 
recurrence of leukemia after the completion of chemotherapy. The trial comprised 
immunophenotyping of serial blood samples along with KIR/HLA genotyping and assessment of 
cytomegalovirus (CMV) serostatus. Results from papers I and II imply a beneficial role of NK cell 
subsets that are less inhibited by HLA while prior CMV infection, which promotes the expression 
of additional KIRs, impacted negatively on relapse risk and survival. Additionally, a single 
nucleotide polymorphism in HLA-B that dictates NK cell inhibition to be preferentially mediated 
by NKG2A impacted positively on outcome in this trial (paper III). The relevance of the 
interplay between activating and HLA-mediated inhibitory signaling was further illustrated in a 
non-malignant setting in paper IV, where modulation of NK cell receptor ligands expressed by 
inflammatory neutrophils was associated with enhanced susceptibility to NK cell cytotoxicity. In 
conclusion, these studies support i) that low-grade KIR-mediated inhibition of NK cells is 
relevant for the benefit of relapse-preventive immunotherapy in AML and ii) that NK cells 
participate in the resolution of inflammation. 
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